Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.

US government stockpiles more drugs, refines pandemic surveillance with wastewater sampling and more as it braces for winter.

Mayne Pharma has received a further setback in its attempt to bring a generic version of NuvaRing to the US market after the FDA issued the firm with another complete response letter.

As Sandoz tries to assist African Union member states by selling its pandemic response portfolio medicines for zero profit, mAbxience has partnered with AstraZeneca to produce a vaccine. And CDMO Hovione has struck a deal with Ligand to boost manufacturing of Captisol, a critical ingredient for Gilead’s remdesivir.